Autotac Bio

AUTOTAC Bio is a South Korean biopharmaceutical company developing next-generation therapeutics based on its proprietary AUTOTAC (Autophagy-Targeting Chimera) platform technology. Founded by Professor Yong-tae Kwon of Seoul National University, the company leverages the autophagy-lysosome system — one of the cell's primary protein degradation pathways — to design bifunctional small molecules that selectively target and eliminate disease-causing proteins. Unlike PROTAC-based degraders that rely on the ubiquitin-proteasome system, AUTOTAC engages the p62 autophagy receptor to direct pathological proteins to lysosomal destruction, enabling degradation of aggregated and high-molecular-weight proteins that proteasome-based approaches cannot address. The platform is broadly applicable across oncology, neurodegeneration (including Alzheimer's disease), metabolic diseases, muscular dystrophy, amyloidosis, and other proteinopathies. Operating under the motto 'Degradation for Betterness,' AUTOTAC Bio aims to become a global pharmaceutical company by commercializing this novel degradation modality as a paradigm-shifting approach to treating previously undruggable diseases.